These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 18154762

  • 1. Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma.
    Lanzl IM, Maier M, Feucht N, Lohmann CP, Kotliar KE.
    Am J Ophthalmol; 2008 Jan; 145(1):185; author reply 186. PubMed ID: 18154762
    [No Abstract] [Full Text] [Related]

  • 2. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
    Frenkel RE, Mani L, Toler AR, Frenkel MP.
    Am J Ophthalmol; 2007 Jun; 143(6):1034-5. PubMed ID: 17524771
    [Abstract] [Full Text] [Related]

  • 3. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study.
    Boyer DS, Goldbaum M, Leys AM, Starita C, V.I.S.I.O.N. Study Group.
    Br J Ophthalmol; 2014 Nov; 98(11):1543-6. PubMed ID: 24997182
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Re: Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin).
    Utman SA, Dhillon B.
    Retina; 2008 Apr; 28(4):667; author reply 667-8. PubMed ID: 18398378
    [No Abstract] [Full Text] [Related]

  • 6. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    Macugen AMD Study GroupDepartment of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri 63110, USA., Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.
    Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
    [Abstract] [Full Text] [Related]

  • 10. Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF).
    Katz B, Goldbaum M.
    Int Ophthalmol Clin; 2006 Sep; 46(4):141-54. PubMed ID: 17060800
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M, Feucht N, Huebner M, Lohmann C.
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Paracentesis before intravitreal injection of bevacizumab.
    Tsui YP, Chiang CC, Tsai YY.
    Can J Ophthalmol; 2008 Apr; 43(2):239; author reply 239-40. PubMed ID: 18347632
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [Abstract] [Full Text] [Related]

  • 16. Comparison of ICare tonometry to Goldmann tonometry for the measurement of intraocular pressure changes following intravitreal anti-vascular endothelial growth factor injection.
    Hui M, Raniga A, Fraser-Bell S, Salem W, Clement C.
    Clin Exp Ophthalmol; 2018 Sep; 46(7):821-823. PubMed ID: 29442417
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety of intravitreal injections in patients receiving warfarin anticoagulation.
    Dayani PN, Siddiqi OK, Holekamp NM.
    Am J Ophthalmol; 2007 Sep; 144(3):451-3. PubMed ID: 17765427
    [Abstract] [Full Text] [Related]

  • 19. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
    Williams AJ, Fekrat S.
    Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868
    [Abstract] [Full Text] [Related]

  • 20. [Application of aptamers to medicine: pharmacological profile and results of clinical trials on pegaptanib sodium (Macugen) for age-related macular degeneration].
    Nagaoka M, Tahara M, Esaka E, Oishi M, Nakane M.
    Nihon Yakurigaku Zasshi; 2009 Aug; 134(2):87-95. PubMed ID: 19672004
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.